Mark Biomedicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.88 M
- Revenue Growth 53.00%
- Profit Growth 759.58%
- Ebitda -11.80%
- Net Worth 7.02%
- Total Assets -15.57%
About Mark Biomedicals
Mark Biomedicals Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 September 2017 (Seven years and five months 11 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.88 M.
Nida Shamim and Aftab Khan serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U85100TG2017PTC119263
-
Company No.
119263
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Sep 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Mark Biomedicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nida Shamim
|
Director | 04-Sep-2017 | Current |
|
Aftab Khan
|
Director | 30-Sep-2017 | Current |
Financial Performance of Mark Biomedicals.
Mark Biomedicals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 53% increase. The company also saw a substantial improvement in profitability, with a 759.58% increase in profit. The company's net worth moved up by a moderate rise of 7.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mark Biomedicals?
In 2021, Mark Biomedicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Markcode Private LimitedAftab Khan is a mutual person
Charges (Loans)
₹1.88 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.19 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Dec 2017 | Others | ₹1.88 M | Open |
How Many Employees Work at Mark Biomedicals?
Unlock and access historical data on people associated with Mark Biomedicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mark Biomedicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mark Biomedicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
